February 14, 2020 10:49 AM ESTUpdated 04:13 PM

AstraZeneca sweeps two cancer drugs to the scrap heap; Epizyme nabs priority review for second rare cancer NDA

ENDPOINTS

→ AstraZeneca swept out two early-stage cancer drugs in its Q4 call on Friday. Out to the dustbin goes the anti-ASCT2 antibody-drug conjugate MEDI7247 and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca sweeps two cancer drugs to the scrap heap; Epizyme nabs priority review for second rare cancer NDA

ENDPOINTS

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

As­traZeneca sweeps two can­cer drugs to the scrap heap; Epizyme nabs pri­or­i­ty re­view for sec­ond rare can­cer NDA

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

AstraZeneca sweeps two cancer drugs to the scrap heap; Epizyme nabs priority review for second rare cancer NDA